Italfarmaco has signed an exclusive agreement with Multicare Pharma to secure regulatory approval and manage the distribution of givinostat (Duvyzat), its oral histone deacetylase inhibitor for Duchenne muscular dystrophy, in Brazil. The move positions givinostat—already approved in multiple regions, including the United States, European Union, and United Kingdom—for entry into Latin America’s most significant rare disease market, with Multicare responsible for supply and on-the-ground commercialization once ANVISA clearance is obtained. Financial terms were not disclosed.
The strategic question is whether a partner-led model can accelerate access and uptake in Brazil’s complex rare disease ecosystem faster than a direct build-out, while ensuring the medical and health-economic evidence needed to cross both ANVISA and CONITEC thresholds. Givinostat’s mutation-agnostic mechanism is a commercial advantage in a landscape long defined by genotype-restricted exon-skipping therapies and standard corticosteroids. Yet that breadth must be matched by persuasive functional outcomes and real-world evidence to convince public payers and private plans that an add-on therapy will deliver meaningful, durable gains in motor function, cardiopulmonary trajectory, and quality of life.
This matters now because Brazil is shifting from judicialization-driven access toward more structured HTA and managed-entry pathways for rare diseases. For patients and neuromuscular centers, a successful approval could broaden treatment options beyond steroids and limited-access exon therapies, particularly for individuals who do not qualify for mutation-specific approaches. For payers, the key questions will be budget impact and operational feasibility, including laboratory and safety monitoring in decentralized settings, given known class considerations for HDAC inhibitors. For competitors, the entry of a mutation-agnostic, oral therapy could reset treatment sequencing and combination strategies, especially if positioned as a backbone alongside steroids and, over time, gene-targeted modalities.
Commercial teams should assume a two-stage challenge: regulatory speed and reimbursement depth. ANVISA has mechanisms for priority review in rare diseases, but time to national access typically hinges on CONITEC’s appraisal and inclusion in clinical protocols for the public system. A private-sector bridge strategy—targeted center activation in primary metro neuromuscular clinics, early medical education, and named-patient pathways where appropriate—will likely be required while national reimbursement is pursued. Pricing will be scrutinized against a crowded and evolving standard of care that now includes steroid innovation and, in some markets, gene therapy. A credible value narrative will require head-to-head or strong indirect comparisons versus corticosteroids alone, clear articulation of functional endpoints such as NSAA trajectories and time to loss of ambulation, and cardiac and respiratory outcomes that resonate with HTA bodies.
For Medical Affairs, success in Brazil will turn on KOL alignment across pediatric neurology and rehab networks, pragmatic data capture through registries and decentralized follow-up, and a robust safety management framework that can scale beyond tertiary centers. Real-world evidence—particularly from heterogeneous, steroid-treated populations—will be the currency for both payer confidence and sustained clinical adoption.
More broadly, the deal highlights a resurgent trend: mid-cap European biopharmas are leaning on specialized Latin American partners to compress time-to-market and de-risk fixed costs in rare diseases. As gene therapy access remains uneven across the region, mutation-agnostic small molecules and steroid-sparing approaches may see faster diffusion—if they arrive with credible outcomes data and adaptable contracting.
The next signal to watch is whether Italfarmaco and Multicare pursue outcomes-based agreements tied to functional milestones and adherence metrics. If they do, Brazil could become a template for rare disease market entry in Latin America—or a cautionary tale if evidence and execution fail to keep pace with payer expectations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
